DK0700445T3 - Stressproteiner og anvendelser deraf - Google Patents
Stressproteiner og anvendelser derafInfo
- Publication number
- DK0700445T3 DK0700445T3 DK94919384T DK94919384T DK0700445T3 DK 0700445 T3 DK0700445 T3 DK 0700445T3 DK 94919384 T DK94919384 T DK 94919384T DK 94919384 T DK94919384 T DK 94919384T DK 0700445 T3 DK0700445 T3 DK 0700445T3
- Authority
- DK
- Denmark
- Prior art keywords
- stress proteins
- individual
- stress
- relates
- immune response
- Prior art date
Links
- 102000002812 Heat-Shock Proteins Human genes 0.000 title abstract 5
- 108010004889 Heat-Shock Proteins Proteins 0.000 title abstract 5
- 230000028993 immune response Effects 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6043—Heat shock proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7338193A | 1993-06-04 | 1993-06-04 | |
PCT/US1994/006362 WO1994029459A1 (en) | 1993-06-04 | 1994-06-06 | Stress proteins and uses therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0700445T3 true DK0700445T3 (da) | 2002-05-13 |
Family
ID=22113364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK94919384T DK0700445T3 (da) | 1993-06-04 | 1994-06-06 | Stressproteiner og anvendelser deraf |
Country Status (11)
Country | Link |
---|---|
US (7) | US6338952B1 (da) |
EP (2) | EP0700445B1 (da) |
JP (2) | JPH08510756A (da) |
AT (1) | ATE212378T1 (da) |
CA (1) | CA2164298A1 (da) |
DE (1) | DE69429723T2 (da) |
DK (1) | DK0700445T3 (da) |
ES (1) | ES2171454T3 (da) |
HK (1) | HK1048496A1 (da) |
PT (1) | PT700445E (da) |
WO (1) | WO1994029459A1 (da) |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0700445B1 (en) * | 1993-06-04 | 2002-01-23 | Whitehead Institute For Biomedical Research | Stress proteins and uses therefor |
US5997873A (en) | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
US5961979A (en) | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
US6773707B1 (en) | 1995-08-18 | 2004-08-10 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
US6331299B1 (en) | 1995-08-18 | 2001-12-18 | Sloan-Kettering Institute For Cancer Research | Method for treatment of cancer and infectious disease and compositions useful in same |
US6719974B1 (en) | 1995-08-18 | 2004-04-13 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
US6761892B1 (en) | 1995-08-18 | 2004-07-13 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
WO1997006821A1 (en) | 1995-08-18 | 1997-02-27 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
US5985270A (en) * | 1995-09-13 | 1999-11-16 | Fordham University | Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes |
US5935576A (en) | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
US5837251A (en) * | 1995-09-13 | 1998-11-17 | Fordham University | Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases |
GB9519737D0 (en) * | 1995-09-27 | 1995-11-29 | Peptide Therapeutics Ltd | Polypeptides and their use in treatment and prophylaxis of auto-immune |
US6130087A (en) * | 1996-10-07 | 2000-10-10 | Fordham University | Methods for generating cytotoxic T cells in vitro |
US7157089B1 (en) | 1996-11-26 | 2007-01-02 | Stressgen Biotechnologies Corporation | Immune responses using compositions containing stress proteins |
ATE318899T1 (de) * | 1996-11-26 | 2006-03-15 | Stressgen Biotechnologies Corp | Fusionsproteine, die stressproteine beinhalten, zum hervorrufen einer immunantwort |
US6017540A (en) | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
US5830464A (en) * | 1997-02-07 | 1998-11-03 | Fordham University | Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy |
WO1998035029A1 (en) * | 1997-02-07 | 1998-08-13 | Vanderbilt University | Synthetic genes for recombinant mycobacterium proteins |
EP1047451A1 (en) * | 1997-02-18 | 2000-11-02 | Whitehead Institute For Biomedical Research | Use of heat shock proteins to deliver moieties into cells |
US6709672B2 (en) | 1997-03-05 | 2004-03-23 | Biotech Tools S.A. | Pharmaceutical or food composition for treating pathologies associated with graft rejection or an allergic or autoimmune reaction |
BE1011033A6 (fr) * | 1997-03-05 | 1999-04-06 | Univ Bruxelles | Composition pharmaceutique et/ou alimentaire pour le traitement de pathologies liees a un rejet de greffe, une reaction allergique ou auto-immune ou du cancer. |
US6319503B1 (en) | 1998-02-19 | 2001-11-20 | Proteinix Company | Heat shock fusion-based vaccine system |
DK1002110T3 (da) * | 1997-08-05 | 2003-05-26 | Stressgen Biotechnologies Corp | Immunsvar mod HPV-antigener fremkaldt af sammensætninger, som omfatter et HPV-antigen og et stressprotein eller en ekspressionsvektor i stand til at ekspressere disse proteiner |
US20050033022A1 (en) * | 1997-09-26 | 2005-02-10 | Smithkline Beecham Biologicals Sa | Fusion proteins comprising HIV-1 Tat and/or Nef proteins |
US6007821A (en) * | 1997-10-16 | 1999-12-28 | Fordham University | Method and compositions for the treatment of autoimmune disease using heat shock proteins |
EP1027070A4 (en) * | 1997-10-31 | 2004-08-18 | Sloan Kettering Institutefor C | CONJUGATES FROM HEAT SHOCK PROTEIN-BINDING PEPTIDES |
AU2003203658B2 (en) * | 1997-10-31 | 2006-07-13 | Sloan-Kettering Institute For Cancer Research | Conjugate heat shock protein-binding peptides |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
BR9714904B1 (pt) | 1997-12-05 | 2010-07-13 | vacina antìgena homóloga e microorganismo transgênico para a mesma. | |
US6451316B1 (en) | 1998-10-05 | 2002-09-17 | University Of Conneticut Health Center | Methods for generating antigen-reactive T cells in vitro |
US6730302B1 (en) | 1998-11-24 | 2004-05-04 | Bristol-Myers Squibb Company | Intracellular targeted delivery of compounds by 70 kD heat shock protein |
CA2352286C (en) * | 1998-11-24 | 2011-07-12 | Bristol-Myers Squibb Company | Intracellular targeted delivery of compounds by 70 kd heat shock protein |
WO2001040292A1 (en) * | 1998-11-27 | 2001-06-07 | Novopharm Biotech Inc. | Antigen-binding fragments specific for tumor associated antigens |
US6497880B1 (en) | 1998-12-08 | 2002-12-24 | Stressgen Biotechnologies Corporation | Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus |
US20020177212A1 (en) * | 1999-05-17 | 2002-11-28 | Board Of Regents, The University Of Texas System | Polypeptide that interacts with heat shock proteins |
US7094873B1 (en) | 1999-05-17 | 2006-08-22 | Board Of Regents, The University Of Texas System | Polypeptide that interacts with heat shock proteins |
AU5926700A (en) | 1999-07-08 | 2001-01-30 | Stressgen Biotechnologies Corporation | Induction of a th1-like response in vitro |
US7378096B2 (en) | 1999-09-30 | 2008-05-27 | Health Research, Inc. | Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
JP2003510334A (ja) | 1999-09-30 | 2003-03-18 | コリクサ コーポレイション | 癌及び感染症の予防及び治療のためのストレスタンパク質組成物及び方法 |
US8128922B2 (en) | 1999-10-20 | 2012-03-06 | Johns Hopkins University | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen |
US6964851B2 (en) * | 1999-12-07 | 2005-11-15 | Stressgen Biotechnologies Corp. | Compositions and methods for detecting stress-inducible proteins |
WO2001051081A1 (en) | 2000-01-14 | 2001-07-19 | Whitehead Institute For Biomedical Research | In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent |
EP1286693A4 (en) | 2000-06-02 | 2005-07-13 | Univ Connecticut Health Ct | COMPLEXES OF ALPHA (2) MACROGLOBULIN AND ANTIGENIC MOLECULES FOR USE IN IMMUNOTHERAPY |
KR100919266B1 (ko) | 2000-06-26 | 2009-09-30 | 엔벤타 바이오파마슈티컬스 코포레이션 | 인간 파필로마 바이러스 치료법 |
ES2454640T3 (es) | 2000-08-03 | 2014-04-11 | Johns Hopkins University | Vacuna molecular que lleva unida un polipéptido de chaperona del retículo endoplasmático a un antígeno |
AU2001295814A1 (en) * | 2000-10-18 | 2002-04-02 | Tengiz Jaliashvili | Vaccine comprising heat stress proteins from herbaceous plants |
IT1319277B1 (it) * | 2000-10-24 | 2003-09-26 | Chiesi Farma Spa | Proteine di fusione utili per il trattamento di immunizzazione dellamalattia di alzheimer. |
BR0206995A (pt) * | 2001-02-05 | 2005-08-16 | Stressgen Biotechnologies Corp | Tratamento do vìrus da hepatite b |
US20020198139A1 (en) * | 2001-05-17 | 2002-12-26 | Deutschman Clifford S. | Method of preventing acute pulmonary cell injury |
US7666581B2 (en) | 2001-08-20 | 2010-02-23 | University Of Connecticut Health Center | Methods for preparing compositions comprising heat shock proteins useful for the treatment of cancer and infectious disease |
US7816491B2 (en) * | 2001-11-08 | 2010-10-19 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Ordered biological nanostructures formed from chaperonin polypeptides |
US7795388B2 (en) * | 2001-11-08 | 2010-09-14 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration (Nasa) | Versatile platform for nanotechnology based on circular permutations of chaperonin protein |
US20060148767A1 (en) * | 2001-12-06 | 2006-07-06 | George Cioca | Use of acyl salicylates as heat shock inducers |
AU2003207744A1 (en) * | 2002-01-30 | 2003-09-02 | Yale University | Transport peptides and uses therefor |
EP2157101B1 (en) | 2002-01-31 | 2014-09-24 | Andromeda Bio Tech Ltd. | HSP peptides and analogs for modulation of immune responses via antigen presenting cells |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
CN1517437B (zh) * | 2003-01-15 | 2010-06-09 | 张聪慧 | 特异性***或胞内感染的疫苗及应用 |
US7420037B2 (en) | 2003-02-13 | 2008-09-02 | Antigenics Inc. | Heat shock protein-based vaccines and immunotherapies |
GB0303507D0 (en) * | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
WO2004090095A2 (en) * | 2003-04-01 | 2004-10-21 | University Of Southern California | Generation of human regulatory t cells by bacterial toxins for the treatment of inflammatory disorders |
US7309491B2 (en) | 2003-04-11 | 2007-12-18 | Antigenics Inc. | Heat shock protein-based vaccines and immunotherapies |
EP1644048B1 (en) | 2003-05-05 | 2015-04-29 | Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein |
GB0321614D0 (en) * | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Vaccines |
RU2251699C1 (ru) * | 2003-09-25 | 2005-05-10 | Киселев Всеволод Иванович | Способ ранней и доклинической диагностики цервикального рака |
EP2145896A3 (en) * | 2003-11-12 | 2010-03-31 | Alfa Biogene International B.V. | Recovery of a heat shock protein |
JP5148116B2 (ja) * | 2004-02-11 | 2013-02-20 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | 癌胎児性抗原融合タンパク質及びその使用 |
CN101001869B (zh) * | 2004-02-11 | 2013-06-19 | P·安杰莱蒂分子生物学研究所 | 癌胚抗原融合物和其用途 |
CN1727362B (zh) * | 2004-07-30 | 2010-12-01 | 中国人民解放军第二军医大学 | 癌胚抗原阳性肿瘤治疗性疫苗的制备及应用 |
AU2005292852B2 (en) | 2004-10-15 | 2011-02-03 | Joe Chiba | Method of immunizing animal, composition for immunization, method of producing antibody, method of producing hybridoma and method of producing monoclonal antibody |
WO2006066089A1 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
WO2006072946A2 (en) | 2005-01-04 | 2006-07-13 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Hsp60, hsp60 peptides and t cell vaccines for immunomodulation |
CA2594040A1 (en) | 2005-01-06 | 2006-07-13 | The Johns Hopkins University | Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines |
US7943133B2 (en) | 2006-02-02 | 2011-05-17 | Boston Biocom Llc | Mesothelin antibody protein fusions and methods of use |
CN101410140B (zh) * | 2006-02-02 | 2016-10-26 | 综合医院公司 | 改造抗体-应激蛋白融合物 |
WO2007116409A2 (en) | 2006-04-11 | 2007-10-18 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Improved vaccines comprising multimeric hsp60 peptide carriers |
WO2009017467A1 (en) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
WO2008040691A1 (en) * | 2006-10-02 | 2008-04-10 | Universiteit Utrecht Holding B.V. | Therapeutic vaccine comprising mycobacterial heat shock protein 70 |
US9085638B2 (en) | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
US20080311145A1 (en) * | 2007-04-04 | 2008-12-18 | Specigen, Inc. | Protein cage immunotherapeutics |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
KR20090007872A (ko) * | 2007-07-16 | 2009-01-21 | 인제대학교 산학협력단 | 자간전증 시에 특이적으로 발현되는 태반 단백질의스크리닝 방법 및 자간전증의 조기 진단 및 예측을 위한마커 |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
EP3329931B1 (en) | 2008-04-18 | 2022-06-08 | The General Hospital Corporation | Immunotherapies employing self-assembling vaccines |
PL2318032T3 (pl) | 2008-06-26 | 2012-08-31 | Orphazyme Aps | Zastosowanie hsp70 jako regulatora aktywności enzymatycznej |
CN101993498B (zh) * | 2008-10-06 | 2013-02-13 | 浙江诺倍威生物技术有限公司 | 腺病毒载体禽流感重组疫苗 |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
RU2015117604A (ru) | 2009-04-03 | 2015-10-27 | Эйдженус Инк. | Способы получения и применения мультишаперон-антигенных комплексов |
GB0916557D0 (en) * | 2009-09-21 | 2009-10-28 | Health Prot Agency | Commensal neisserial stress protein complexes |
EP3187585A1 (en) | 2010-03-25 | 2017-07-05 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
CA2807514A1 (en) | 2010-08-06 | 2012-02-09 | The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services | Biomarkers for prostate cancer and methods for their detection |
US9662375B2 (en) | 2010-11-30 | 2017-05-30 | Orphazyme Aps | Methods for increasing intracellular activity of Hsp70 |
DK2691530T3 (da) | 2011-06-10 | 2018-05-22 | Univ Oregon Health & Science | Cmv-glycoproteiner og rekombinante vektorer |
EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
CN103364569B (zh) * | 2013-07-30 | 2015-06-17 | 广西壮族自治区兽医研究所 | 牛隐孢子虫elisa检测试剂盒 |
EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
EP2873423B1 (en) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3193840B1 (en) | 2014-09-15 | 2021-05-19 | Orphazyme A/S | Arimoclomol formulation |
CN104392125A (zh) * | 2014-11-18 | 2015-03-04 | 宁波江丰生物信息技术有限公司 | 一种基于统计评分的荧光染色结核杆菌检测方法 |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
WO2017011380A1 (en) * | 2015-07-14 | 2017-01-19 | The Board Of Trustees Of The University Of Illinois | Vaccine and methods for detecting and preventing filariasis |
WO2017178029A1 (en) | 2016-04-13 | 2017-10-19 | Orphazyme Aps | Heat shock proteins and cholesterol homeostasis |
AU2017255959B2 (en) | 2016-04-29 | 2020-10-15 | Zevra Denmark A/S | Arimoclomol for treating glucocerebrosidase associated disorders |
CA3202568A1 (en) | 2020-11-19 | 2022-05-27 | Zevra Denmark A/S | Processes for preparing arimoclomol citrate and intermediates thereof |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666847A (en) * | 1981-01-16 | 1987-05-19 | Collaborative Research, Inc. | Recombinant DNA means and method |
US4557931A (en) * | 1982-12-02 | 1985-12-10 | Regents Of The University Of California | Antigenic compositions and methods for using same |
NO172595C (no) | 1983-02-07 | 1993-08-11 | Battelle Memorial Institute | Fremgangsmaate og ekspresjonsplasmid for fremstilling av hemagglutinin under kontroll av drosophila hsp-promoter |
US4797359A (en) * | 1983-05-10 | 1989-01-10 | Board Of Regents, The University Of Texas System | Heat shock regulated production of selected and fused proteins in yeast |
GB8404280D0 (en) * | 1984-02-17 | 1984-03-21 | Stanford J L | Biological preparations |
IL71683A0 (en) | 1984-04-27 | 1984-09-30 | Yeda Res & Dev | Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria |
US4918164A (en) * | 1987-09-10 | 1990-04-17 | Oncogen | Tumor immunotherapy using anti-idiotypic antibodies |
US4784941A (en) * | 1985-04-08 | 1988-11-15 | Genetic Systems Corporation | Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV |
JPS62164696A (ja) | 1986-01-06 | 1987-07-21 | エフ.ホフマン ― ラ ロシュ アーゲー | HTLV−3gag遺伝子の発現 |
US4734362A (en) * | 1986-02-03 | 1988-03-29 | Cambridge Bioscience Corporation | Process for purifying recombinant proteins, and products thereof |
US4906742A (en) | 1986-07-31 | 1990-03-06 | Whitehead Institute For Biomedical Research | Encoding antigens of M. Leprae |
NL8701163A (nl) | 1986-09-09 | 1988-04-05 | Nederlanden Staat | Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits. |
JP2501107B2 (ja) | 1986-10-20 | 1996-05-29 | キヤノン株式会社 | 光電変換装置 |
WO1988005823A2 (en) | 1987-02-02 | 1988-08-11 | Whitehead Institute For Biomedical Research | Mycobacterium tuberculosis genes encoding protein antigens |
US4952395A (en) | 1987-02-26 | 1990-08-28 | Scripps Clinic And Research Foundation | Mycobacterial recombinants and peptides |
US5504005A (en) * | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
WO1990015873A1 (en) * | 1989-06-19 | 1990-12-27 | Whitehead Institute For Biomedical Research | Vector-mediated genomic insertion and expression of dna in bcg |
US4918166A (en) * | 1987-04-10 | 1990-04-17 | Oxford Gene Systems Limited | Particulate hybrid HIV antigens |
US5256767A (en) * | 1987-06-10 | 1993-10-26 | The Immune Response Corporation | Retroviral antigens |
NL8703107A (nl) | 1987-12-22 | 1989-07-17 | Nederlanden Staat | Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten. |
JPH01179687A (ja) | 1987-12-30 | 1989-07-17 | Chemo Sero Therapeut Res Inst | Hiv融合蛋白質 |
US5204259A (en) * | 1988-05-06 | 1993-04-20 | Pharmacia Genetic Engineering, Inc. | Methods and systems for producing HIV antigens |
CA1338778C (en) * | 1988-06-15 | 1996-12-10 | Richard A. Young | Stress proteins and uses therefor |
US4916166A (en) * | 1988-10-17 | 1990-04-10 | The Dow Chemical Company | Insulating alkenyl aromatic polymer foam |
US5114844A (en) | 1989-03-14 | 1992-05-19 | Yeda Research And Development Co., Ltd. | Diagnosis and treatment of insulin dependent diabetes mellitus |
EP0467972A4 (en) | 1989-04-06 | 1992-09-02 | Washington State University Research Foundation | Rickettsial antigens for vaccination and diagnosis |
GB8919321D0 (en) | 1989-08-25 | 1989-10-11 | Univ London | Treatment of chronic inflammatory conditions |
GB9007194D0 (en) | 1990-03-30 | 1990-05-30 | Wellcome Found | Live vaccines |
GB9024320D0 (en) | 1990-11-08 | 1990-12-19 | Univ London | Treatment of uveitis |
ATE154759T1 (de) | 1990-11-08 | 1997-07-15 | Univ London | Mycobacterium als adjuvans für antigene |
GB2251186A (en) | 1990-12-04 | 1992-07-01 | Randall Neal Gatz | Polypeptide for use in treatment of autoimmune disease |
EP0521220A1 (en) | 1991-06-14 | 1993-01-07 | Institut Pasteur | Recombinant immunogenic actinomycetale |
IT1262896B (it) * | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
US5580563A (en) * | 1992-05-01 | 1996-12-03 | Tam; James P. | Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof |
IL102687A (en) * | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
US5256259A (en) * | 1993-03-29 | 1993-10-26 | Lloyd Berg | Separation of hexane from vinyl acetate by azeotropic distillation |
EP0700445B1 (en) * | 1993-06-04 | 2002-01-23 | Whitehead Institute For Biomedical Research | Stress proteins and uses therefor |
CA2168952A1 (en) * | 1993-08-11 | 1995-02-16 | Lynn E. Spitler | Prostatic cancer vaccine |
US5961979A (en) | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
IL109790A0 (en) | 1994-05-25 | 1994-08-26 | Yeda Res & Dev | Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines |
GB9419979D0 (en) | 1994-10-04 | 1994-11-16 | Medeva Holdings Bv | Vaccine compositions |
WO1997006821A1 (en) | 1995-08-18 | 1997-02-27 | Sloan-Kettering Institute For Cancer Research | Heat shock protein-based vaccines and immunotherapies |
US5935576A (en) * | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
WO1997026910A2 (de) | 1996-01-27 | 1997-07-31 | Max-Delbrück-Centrum für Molekulare Medizin | Tumorimpfstoff für die immuntherapie von malignen tumoren |
US6455493B1 (en) * | 1996-09-20 | 2002-09-24 | University Of New Mexico | Methods for using heat shock proteins |
ATE318899T1 (de) | 1996-11-26 | 2006-03-15 | Stressgen Biotechnologies Corp | Fusionsproteine, die stressproteine beinhalten, zum hervorrufen einer immunantwort |
EP1047451A1 (en) * | 1997-02-18 | 2000-11-02 | Whitehead Institute For Biomedical Research | Use of heat shock proteins to deliver moieties into cells |
DK1002110T3 (da) | 1997-08-05 | 2003-05-26 | Stressgen Biotechnologies Corp | Immunsvar mod HPV-antigener fremkaldt af sammensætninger, som omfatter et HPV-antigen og et stressprotein eller en ekspressionsvektor i stand til at ekspressere disse proteiner |
AU5926700A (en) * | 1999-07-08 | 2001-01-30 | Stressgen Biotechnologies Corporation | Induction of a th1-like response in vitro |
WO2001051081A1 (en) | 2000-01-14 | 2001-07-19 | Whitehead Institute For Biomedical Research | In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete atp binding domain and is cd4+ t cell-independent |
-
1994
- 1994-06-06 EP EP94919384A patent/EP0700445B1/en not_active Revoked
- 1994-06-06 DK DK94919384T patent/DK0700445T3/da active
- 1994-06-06 PT PT94919384T patent/PT700445E/pt unknown
- 1994-06-06 AT AT94919384T patent/ATE212378T1/de not_active IP Right Cessation
- 1994-06-06 JP JP7502024A patent/JPH08510756A/ja active Pending
- 1994-06-06 DE DE69429723T patent/DE69429723T2/de not_active Expired - Fee Related
- 1994-06-06 ES ES94919384T patent/ES2171454T3/es not_active Expired - Lifetime
- 1994-06-06 EP EP01203598A patent/EP1221488A1/en not_active Withdrawn
- 1994-06-06 WO PCT/US1994/006362 patent/WO1994029459A1/en active IP Right Grant
- 1994-06-06 CA CA002164298A patent/CA2164298A1/en not_active Abandoned
- 1994-11-03 US US08/336,251 patent/US6338952B1/en not_active Expired - Fee Related
-
1995
- 1995-06-05 US US08/461,722 patent/US6335183B1/en not_active Expired - Fee Related
-
1999
- 1999-12-21 US US09/468,041 patent/US6482614B1/en not_active Expired - Fee Related
-
2002
- 2002-01-14 US US10/046,649 patent/US20030073094A1/en not_active Abandoned
-
2003
- 2003-01-09 HK HK03100228.1A patent/HK1048496A1/zh unknown
-
2004
- 2004-06-28 US US10/880,771 patent/US20050163792A1/en not_active Abandoned
-
2005
- 2005-09-06 JP JP2005258485A patent/JP2006042823A/ja active Pending
-
2006
- 2006-04-10 US US11/401,687 patent/US20060177461A1/en not_active Abandoned
- 2006-04-10 US US11/401,608 patent/US7501234B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0700445B1 (en) | 2002-01-23 |
PT700445E (pt) | 2002-07-31 |
WO1994029459A1 (en) | 1994-12-22 |
ES2171454T3 (es) | 2002-09-16 |
US20060177460A1 (en) | 2006-08-10 |
EP0700445A1 (en) | 1996-03-13 |
CA2164298A1 (en) | 1994-12-22 |
DE69429723T2 (de) | 2002-09-26 |
US6338952B1 (en) | 2002-01-15 |
ATE212378T1 (de) | 2002-02-15 |
US6482614B1 (en) | 2002-11-19 |
US20050163792A1 (en) | 2005-07-28 |
HK1048496A1 (zh) | 2003-04-04 |
US20030073094A1 (en) | 2003-04-17 |
US6335183B1 (en) | 2002-01-01 |
EP1221488A1 (en) | 2002-07-10 |
US20060177461A1 (en) | 2006-08-10 |
JPH08510756A (ja) | 1996-11-12 |
US7501234B2 (en) | 2009-03-10 |
JP2006042823A (ja) | 2006-02-16 |
DE69429723D1 (de) | 2002-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0700445T3 (da) | Stressproteiner og anvendelser deraf | |
ATE127345T1 (de) | Stressproteine und verwendungen dafür. | |
DK382786D0 (da) | Overfladeaktivt rekombinant-alveolarprotein | |
DE69533544D1 (de) | Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten | |
DK0561907T3 (da) | Proteiner med ændrede epitoper og fremgangsmåder til fremstilling deraf | |
DK0935607T3 (da) | Oplöselige monovalente og multivalente MHC klasse II-fusionsproteiner samt anvendelser deraf | |
DE69333673D1 (de) | Epitope von Stress Proteinen | |
ATE262038T1 (de) | Br96 mutantantikörper die mit menschlichen karzinomen reagieren | |
ATE64619T1 (de) | Menschliches apolipoprotein a1 sowie dessen variante, exprimiert in escherichia coli. | |
PT741788E (pt) | Inducao de tolerancia com proteinas de fusao tolerogenicas | |
ATE273388T1 (de) | Veränderte menschliche c3-proteine | |
DE60139515D1 (de) | Neue Polypeptide aus Bienengift und dessen Gebrauchsverfahren | |
FR2692282B1 (fr) | Clonage du gene codant pour la proteine gp28.5 de t. gondii; fragments peptidiques issus de ladite proteine et leurs applications. | |
DK278289A (da) | Ekspressionsvektorer, deres fremstilling og anvendelse til fremstilling af ufusionerede proteiner i mikroorganismer | |
FI961584A0 (fi) | C-reaktiivisista proteiinifragmenteista johdetut oligopeptidit | |
HU9500185D0 (en) | Vaccines against metazoan parasites | |
WO1995008631A3 (en) | Target antigens of transmission blocking antibodies for malaria parasites | |
DK1040191T3 (da) | RANTES-mutanter og terapeutiske anvendelser heraf | |
ATE245661T1 (de) | Natürliche menschliche igm antikörper | |
TH30771A (th) | แอนติ- Fas รีคอมบีแนนท์ แอนติบอดี และ DNA ของส่วนดังกล่าว | |
GR3018066T3 (en) | Schizosaccharomyces specific polypeptide. |